Evidence map›Paper›PMID 33715635›Full record

ArticleAlzheimer's research & therapy2021

Enhancing magnetic resonance imaging-driven Alzheimer's disease classification performance using generative adversarial learning.

Xiao Zhou, Shangran Qiu, Prajakta S Joshi, Chonghua Xue, Ronald J Killiany, Asim Z Mian, Sang P Chin, Rhoda Au, Vijaya B Kolachalama

Open access · goldAbstract read
In one paragraph

Article in Alzheimer's research & therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 2 pooled it
6.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 78 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Machine Learning in Clinical Trials: A Primer with Applications to Neurology.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023
    Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Xiao Zhou *Section of Computational Biomedicine, Department of Medicine, Boston University School of Medicine, 72 E. Concord Street, Evans 636, Boston, MA, 02118, USA.
Shangran Qiu *Section of Computational Biomedicine, Department of Medicine, Boston University School of Medicine, 72 E. Concord Street, Evans 636, Boston, MA, 02118, USA.
Prajakta S JoshiDepartment of Anatomy and Neurobiology, Boston University School of Medicine, Boston, MA, USA.
Chonghua XueSection of Computational Biomedicine, Department of Medicine, Boston University School of Medicine, 72 E. Concord Street, Evans 636, Boston, MA, 02118, USA.
Ronald J KillianyDepartment of Anatomy and Neurobiology, Boston University School of Medicine, Boston, MA, USA.
Asim Z MianDepartment of Radiology, Boston University School of Medicine, Boston, MA, USA.
Sang P ChinDepartment of Computer Science, College of Arts & Sciences, Boston University, Boston, MA, USA.
Rhoda AuDepartment of Anatomy and Neurobiology, Boston University School of Medicine, Boston, MA, USA.
Vijaya B KolachalamaSection of Computational Biomedicine, Department of Medicine, Boston University School of Medicine, 72 E. Concord Street, Evans 636, Boston, MA, 02118, USA. vkola@bu.edu.ORCID 0000-0002-5312-8644
Boston University · US

Funding

TBDU19AG068753 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Rhoda Au · 2020 to 2026
$42.4M
South Texas Alzheimer's Disease Research CenterP30AG066546 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Mohamad Habes · 2021 to 2026
$24.0M
EPIDEMIOLOGY OF DEMENTIA IN THE FRAMINGHAM STUDYR01AG008122 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI AU, RHODA, SESHADRI, SUDHA · 1989 to 2015
$14.4M
MRI, Genetics &Cognitive Precursors of AD &DementiaR01AG016495 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI AU, RHODA · 1999 to 2016
$12.5M
Temporal Trends, Novel Imaging and Molecular Characterization of Preclinical and Clinical Alzheimer's Disease in the Framingham CohortsR01AG054076 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI DECARLI, CHARLES, SESHADRI, SUDHA · 2016 to 2020
$12.3M
MRI, Cognitive, Genetic & Biomarker Precursors of AD & Dementia in Young AdultsR01AG033040 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI AU, RHODA, SESHADRI, SUDHA · 2009 to 2019
$11.2M
Re-visiting Methods for MCI Diagnosis to Improve Biomarker and Trial FindingsR01AG049810 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BONDI, MARK W, EDLAND, STEVEN DYAL · 2016 to 2020
$3.7M
Precision Brain Health Monitoring for Alzheimer's Disease Risk Detection in the Framingham Study: Black & AA Recruitment SupplementRF1AG072654 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI AU, RHODA, GOLDSTEIN, LEE E. · 2021 to 2023
$2.4M
Role of the Werner syndrome protein complex in the metabolism of chromosome endsR01AG034156 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI COMAI, LUCIO · 2010 to 2014
$1.8M
Cognitive Heterogeneity in those with high Alzheimer's Disease RiskRF1AG062109 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI AU, RHODA · 2020 to 2021
$1.8M
Cognitive heterogeneity in those with high Alzheimer's Disease RiskR01AG062109 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Rhoda Au, Vijaya B. Kolachalama · 2025 to 2026
$1.6M
Precision Brain Health Monitoring for Alzheimer's Disease Risk Detection in the Framingham StudyR01AG072654 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Rhoda Au, LEE E. GOLDSTEIN · 2025 to 2026
$1.1M
NCI NIH HHS R21 CA253498NCI NIH HHS R21-CA253498NIA NIH HHS P30 AG066546NIA NIH HHS R01 AG008122NIA NIH HHS R01 AG016495NIA NIH HHS R01 AG033040NIA NIH HHS R01 AG034156NIA NIH HHS R01 AG049810NIA NIH HHS R01 AG054076NIA NIH HHS R01 AG062109NIA NIH HHS R01-AG062109NIA NIH HHS R01 AG072654NIA NIH HHS R56 AG062109NIA NIH HHS RF1 AG062109NIA NIH HHS RF1 AG072654NIA NIH HHS U19 AG068753
6 · The paper itself

Abstract

backgroundGenerative adversarial networks (GAN) can produce images of improved quality but their ability to augment image-based classification is not fully explored. We evaluated if a modified GAN can learn from magnetic resonance imaging (MRI) scans of multiple magnetic field strengths to enhance Alzheimer's disease (AD) classification performance.

methodsT1-weighted brain MRI scans from 151 participants of the Alzheimer's Disease Neuroimaging Initiative (ADNI), who underwent both 1.5-Tesla (1.5-T) and 3-Tesla imaging at the same time were selected to construct a GAN model. This model was trained along with a three-dimensional fully convolutional network (FCN) using the generated images (3T*) as inputs to predict AD status. Quality of the generated images was evaluated using signal to noise ratio (SNR), Blind/Referenceless Image Spatial Quality Evaluator (BRISQUE) and Natural Image Quality Evaluator (NIQE). Cases from the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL, n = 107) and the National Alzheimer's Coordinating Center (NACC, n = 565) were used for model validation.

resultsThe 3T*-based FCN classifier performed better than the FCN model trained using the 1.5-T scans. Specifically, the mean area under curve increased from 0.907 to 0.932, from 0.934 to 0.940, and from 0.870 to 0.907 on the ADNI test, AIBL, and NACC datasets, respectively. Additionally, we found that the mean quality of the generated (3T*) images was consistently higher than the 1.5-T images, as measured using SNR, BRISQUE, and NIQE on the validation datasets.

conclusionThis study demonstrates a proof of principle that GAN frameworks can be constructed to augment AD classification performance and improve image quality.

Indexed as

Alzheimer DiseaseAustraliaBrainHumansMagnetic Resonance ImagingNeuroimagingAlzheimer’s diseaseDeep learningFully convolutional networkGenerative adversarial networkMagnetic field strengthMagnetic resonance imaging

Identifiers

PMID33715635
PMCPMC7958452
OpenAlexW3138368401

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.